André Zimerman (@andrezimerman) 's Twitter Profile
André Zimerman

@andrezimerman

Postdoctoral Research Fellow @TIMIStudyGroup. Cardiologist & PhD Graduate @HCPA_, UFRGS. I like lipids, preventive cardiology, #rstats, @gremio.

ID: 726671044455575552

linkhttps://bio.site/andrezimerman calendar_today01-05-2016 07:14:12

1,1K Tweet

1,1K Followers

823 Following

André Zimerman (@andrezimerman) 's Twitter Profile Photo
André Zimerman
@andrezimerman

5 months ago

In patients with TGs >150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%. Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk. Proud to be a part of this team. Full paper now in NEJM. TIMI Study Group Brian Bergmark

In patients with TGs &gt;150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%. Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk. Proud to be a part of this team. Full paper now in <a href="/NEJM/">NEJM</a>. <a href="/TIMIStudyGroup/">TIMI Study Group</a> <a href="/BrianBergmark/">Brian Bergmark</a>